Naslov
Prophylaxis of RhD immunisation in Croatia on the treshold of its accession to the European Union

Autori
Jaklin, Gordana ; Golubić Ćepulić, Branka

Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, ostalo

Skup
15th ISBT European Regional Conference

Mjesto i datum
Atena, Grčka, 2.-6.7

Vrsta sudjelovanja
Poster

Vrsta recenzije
Podatak o recenziji nije dostupan

Ključne riječi
Prophylaxis, RhD immunisation

Sažetak
N Croatia national guidelines for the use of RHD gamma globulin were laid down in the year 2000. In accordance with the guidelines, RHD gamma globulin is administered intramuscularly in doses of 250– 300mg and should be given to RHD negative women after delivery of RH positive children, after abortions, in Week 28 of their first pregnancy, as well as in cases pregnancies with an increased risk of fetomaternal hemorrhage. As to the latter, detection and measurement of fetomaternal hemorrhage are recommended. Three years after the issuance of the guidelines a survey was conducted regarding the use of RHD gamma globulin that involved 33 health institutions across the country. As many as 38601 deliveries and 10 974 abortions were reported in 2003. The institutions reported the usage of 5103 doses of 250mg RHD gamma globulin or 110 doses/1000 deliveries + abortions. We compared our data with those obtained from similar surveys conducted in 1999, i.e. before the issuance of the guidelines. In that year 4407 deliveries and 1400 abortions were reported, and 6125 doses of RHD gamma globulin or 100 doses/1000 deliveries + abortions were administered. Institutions were then divided into four categories: clinical hospitals, general hospitals with the capacity of 400–600 beds, general hospitals with the capacity of 100–400 beds, and institutions of rather limited capacity with gynaecology department. The range of the consumption of RHD gamma globulin/1000 deliveries + abortions in the first category was 73–167 with the median being 119 ; in the second category there were 73–115 doses with the median being 92, in the third category 55–128 doses with the median being 88, while in the fourth category the range was 10– 191 doses with the median of 79 doses. The number of pregnancies which should have been protected with RHD immunization in 2003 year was obtained by the following formula: (frequency of RHD negative subjects) ¥ (frequency of the R gene) = 0.17 ¥ 0.59 = 0.10. If a complete antenatal and postnatal preventive measures involving RHD immunization had been taken in 2003, 12287 doses of RHD gamma globulin or 250mg/1000 deliveries + abortions should have been given. Our research has shown that, despite of the national guidelines adopted in 2000, the prevention of the RHD immunization in pregnant women is still not adequate in Croatia. In fact, it has not improved since a year prior to the adoption of the guidelines. It has also been established that the category of the institution is a factor influencing the implementation of the protective measures. We consider that much more should be done on informing both women and gynaecologists about the importance of prophylaxis of the RHD immunization.

Izvorni jezik
Engleski

Znanstvena područja
Biotehnologija u biomedicini (prirodno područje, biomedicina i zdravstvo, biotehničko područje)

POVEZANOST RADA